Mark Purcell
Stock Analyst at Morgan Stanley
(0.88)
# 3,897
Out of 4,996 analysts
6
Total ratings
33.33%
Success rate
-6.81%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Purcell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNY Sanofi | Upgrades: Overweight | $56 → $58 | $45.54 | +27.36% | 2 | Sep 8, 2025 | |
| NVS Novartis AG | Initiates: Equal-Weight | $114 | $123.65 | -7.80% | 1 | Jan 23, 2024 | |
| GSK GSK plc | Initiates: Equal-Weight | $44 | $39.85 | +10.41% | 1 | Jan 23, 2024 | |
| AZN AstraZeneca | Initiates: Overweight | $85 | $73.76 | +15.24% | 1 | Jan 23, 2024 | |
| NVO Novo Nordisk | Initiates: Overweight | $120 | $55.61 | +115.79% | 1 | Jan 23, 2024 |
Sanofi
Sep 8, 2025
Upgrades: Overweight
Price Target: $56 → $58
Current: $45.54
Upside: +27.36%
Novartis AG
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $114
Current: $123.65
Upside: -7.80%
GSK plc
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $44
Current: $39.85
Upside: +10.41%
AstraZeneca
Jan 23, 2024
Initiates: Overweight
Price Target: $85
Current: $73.76
Upside: +15.24%
Novo Nordisk
Jan 23, 2024
Initiates: Overweight
Price Target: $120
Current: $55.61
Upside: +115.79%